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Abstract
Myocardial differentiation is associated with the activation and expression of an array of cardiac specific genes. However,
the transcriptional networks that control cardiac gene expression are not completely understood. Myocardin is a cardiac
and smooth muscle-specific expressed transcriptional coactivator of Serum Response Factor (SRF) and is able to potently
activate cardiac and smooth muscle gene expression during development. We hypothesize that myocardin discriminates
between cardiac and smooth muscle specific genes by associating with distinct co-factors. Here, we show that myocardin
directly interacts with Tbx5, a member of the T-box family of transcription factors involved in the Holt-Oram syndrome. Tbx5
synergizes with myocardin to activate expression of the cardiac specific genes atrial natriuretic factor (ANF) and alpha
myosin heavy chain (a-MHC), but not that of smooth muscle specific genes SM22 or smooth muscle myosin heavy chain
(SM-MHC). We found that this synergistic activation of shared target genes is dependent on the binding sites for Tbx5, T-box
factor-Binding Elements (TBEs). Myocardin and Tbx5 physically interact and their interaction domains were mapped to the
basic domain and the coil domain of myocardin and Tbx5, respectively. Our analysis demonstrates that the Tbx5G80R
mutation, which leads to the Holt-Oram syndrome in humans, failed to synergize with myocardin to activate cardiac gene
expression. These data uncover a key role for Tbx5 and myocardin in establishing the transcriptional foundation for cardiac
gene activation and suggest that the interaction of myocardin and Tbx5 maybe involved in cardiac development and
diseases.
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Introduction
Heart formation is one of the earliest morphogenic events
during animal development. The development of the heart is
under the control of a complex transcriptional network, and dys-
regulation of the expression or genetic mutation of cardiac genes
often leads to abnormality in the morphology and the function of
the heart [1,2]. Congenital heart defects (CHD) are found in more
than 1% life birth in human beings and are the most common
diseases affecting children [3]. One type of CHD, the Holt-Oram
syndrome (HOS) occurs in a frequency of 1 of 100,000 with
defects in the heart and upper limbs [4]. Mutations of Tbx5, a
member of the T-box family of transcription factors, have been
identified as a causative gene of the HOS [5,6]. The Tbx5
mutations found from the HOS patients include missense
mutations, deletions that induce open reading frame shifts, and
premature truncations [5,6,7,8].
Whereas haploinsufficiency of Tbx5 in transgenic mice mimics
the HOS, homologous deletion of the Tbx5 gene led to early
embryonic lethality [9]. The fact that deletion of only one copy of
the Tbx5 genomic sequence already resulted in defects in the
mouse model further suggested that the dosage of the Tbx5 gene is
critical for the development of the heart and the expression of
Tbx5 downstream genes [10]. Consistent with this view,
overexpression of Tbx5 under the b-myosin heavy chain promoter
in embryonic mouse hearts led to a failure of ventricular
development and embryonic lethality in mice [11]. Overexpres-
sion of Tbx5 via gene duplication severely affects the development
of the heart and limbs in human patients [12,13]. Furthermore,
carriers of Tbx5 mutations show different levels of impairments on
the development of the heart and limbs on an individual basis and
it was observed that the severity of defects varies even between
patients with the same genetic background [7,13]. Intriguingly, it
was also noticed that some Tbx5 mutations lead to more severe
abnormity than others [4]. The Tbx5 point mutation G80R
displays more severe defects in the heart, in contrast to that of the
R237Q mutation [14]. However, the molecular mechanisms
underlying those observations are not fully understood.
Tbx5 cooperates with other transcriptional factors to regulate
the expression of its target genes [8]. Tbx5 has been shown to
interact with Nkx2.5, GATA4, Mef2c, Sall4 and TAZ to
synergistically activate target genes expression in cardiomyocytes
[14,15,16,17,18,19,20,21]. The Tbx5 mutants G80R and R237Q
were reported to disrupt its synergy with Nkx2.5 and GATA4
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24242[14]. We have previously found that Tbx5 missense mutations
affected its function in activating cardiac gene expression [22].
Myocardin is a potent transcription cofactor for serum response
factor (SRF) and is expressed in smooth and cardiac muscles [23].
Myocardin contains no DNA-binding domains and it functions by
forming a stable complex with SRF to regulate the expression of
cardiac and smooth muscle genes that are under the control of
promoters containing the consensus sequence CC(A/T)6GG or
CArG box [24,25]. Myocardin is required for smooth muscle gene
expression and myocardin knock out mice showed severe defects
in smooth cell differentiation, cardiovascular insufficiency and
embryonic lethality [26]. Two myocardin homologues, myocardin
related transcription factor -A and –B (MRTF-A and -B), are also
potent SRF cofactors [27]. Genetic studies revealed that
myocardin and MRTFs play critical roles in a variety of biological
processes, including vascular smooth muscle development, aortic
vessel patterning, mammary myoepithelium formation and others
[26,28,29,30,31,32]. In addition to SRF, myocardin interacts with
several other transcriptional regulators including GATA4,
Smad1/3, p300, HDAC4/5, NF-kB, Foxo4 and such interaction
modulates the transactivity of myocardin and the expression of the
target genes [33,34,35,36,37,38]. However, how exactly myocar-
din discriminates between cardiac and smooth muscle specific
genes is still unknown. We hypothesize that myocardin activate
cardiac or smooth muscle specific genes by collaborating with
distinct transcriptional co-factors. In this study, we report that
myocardin physically interacts with Tbx5 to synergistically activate
the expression of cardiac genes, but not that of smooth muscle
genes.
Results
Myocardin and Tbx5 synergistically activate cardiac
reporter genes
Myocardin potently activates both cardiac and smooth muscle
gene expression in a CArG-dependent manner [24]. We
hypothesize that myocardin may interact and synergistically
cooperate with other cardiac and smooth muscle expressed
transcription factors for its distinct function in those two cell
types. Previous reports showed that both myocardin and Tbx5
activate the expression of cardiac-specific genes, including ANF
[9,10,23]. Using luciferase reporters driven by promoters of
cardiac or smooth muscle genes, we tested whether myocardin and
Tbx5 could synergistically activate these reporter genes in
transfected COS-7 cells. As shown in Fig. 1A, both Tbx5 and
myocardin activate the ANF luciferase reporter and they
synergistically activate the reporter when both proteins were co-
transfected together. Note that myocardin is a potent transacti-
vator and activates the reporter gene to a much higher level than
that of Tbx5. Similarly, myocardin and Tbx5 synergistically
activate a luciferase reporter driven by the promoter of cardiac-
specific alpha myosin heavy chain (a-MHC) gene (Fig. 1B). To test
whether myocardin and Tbx5 have similar effects on the
expression of smooth muscle genes, SM22 and smooth muscle
myosin heavy chain (SM-MHC) promoter luciferase reporters
were assayed. Consistent with prior reports [23,39], myocardin
but not Tbx5 activates both SM22 and SM-MHC promoter
luciferase reporters (Fig. 1C, 1D). However, when both myocardin
and Tbx5 were co-transfected with the luciferase reporters, no
synergy was observed (Fig. 1C, 1D).
To test whether Tbx5 and myocardin could synergistically
activate the ANF promoter in cardiomyocytes, we transfected both
myocardin and Tbx5 expression plasmids, together with the ANF
luciferase reporter, into primarily cultured neonatal rat cardiomy-
ocytes. As shown in Fig. 1E, whereas both myocardin and Tbx5
can activate the ANF luciferase reporter, their activities were
synergized in cardiomyocytes. Together, these results demonstrate
that myocardin and Tbx5 synergistically active the expression of
cardiac reporter genes but not that of smooth muscle genes.
The TBE sites of the ANF promoter are required for the
synergy between myocardin and Tbx5
The promoter/enhancer of the ANF gene contains multiple cis-
elements for several transcription factors, including that of Nkx2.5-
binding site (NKE), MEF2-binding site (MEF), GATA-element
(GATA), T-box factor-Binding Element (TBE) as well as SRF-
binding site (CArG) [1,9]. To define the cis-elements of the ANF
promoter that are responsible for the synergy of myocardin and
Tbx5, luciferase reporters driven by truncated ANF promoter
sequences were tested in luciferase reporter assays (Fig. 2A). There
are two CArG boxes, CArG-F and CArG-N, and two TBEs,
TBE2 and TBE1, on the promoter/enhancer of the ANF gene.
Analysis of a series of ANF promoter deletion mutations revealed a
decrease in the overall potential of myocardin or Tbx5 to activate
the reporter gene. However, myocardin and Tbx5 still displayed
synergy on the minimal ANF promoter (ANF115) in which a single
CArG and TBE remain (Fig. 2A), suggesting that these cis-
elements are sufficient to mediate the synergy of myocardin and
Tbx5 on the ANF promoter reporter gene.
Next, we mutated the TBE site from the ANF115 minimal
promoter and tested the activities of myocardin and Tbx5 to
activate the reporter gene. Interestingly, we found that the TBE
mutation abolished the synergy between myocardin and Tbx5 to
activate this reporter (Fig. 2B). Conversely, we mutated the CArG
box from the ANF 115 minimal promoter and found that the
CArG mutation did not completely abolish the synergy between
myocardin and Tbx5, though their overall activity was signifi-
cantly decreased (Fig. 2C). To further define the cis-element
requirement for myocardin and Tbx5 synergy, we mutated both
CArG boxes from the ANF638 promoter and test their activation
by myocardin and Tbx5. Interestingly, myocardin and Tbx5 were
able to synergistically activate this mutant promoter (Fig. 2D),
indicating that the TBE sites were sufficient to mediate the synergy
of myocardin and Tbx5. This notion was further supported by the
observation that myocardin and Tbx5 were able to synergistically
activate a luciferase reporter that is driven by tandem repeats of
four TBEs (Fig. 2E). Together, our data suggest that the T-box
factor-Binding Elements (TBEs) are essential for the synergy of
myocardin and Tbx5 to activate the promoter of the cardiac gene
ANF.
Myocardin and Tbx5 directly interact
To test whether Tbx5 and myocardin interact directly, co-
immunoprecipitation (Co-IP) assays were performed with cell
extracts in which Myc- or Flag-tagged myocardin and Tbx5 were
overexpressed in COS-7 cells. When Flag-Tbx5 was precipitated
using anti-Flag antibodies, Tbx5-associated Myc-myocardin was
readily detected by Western blotting (Fig. 3A). No such interaction
was detected when either Flag-Tbx5 or Myc-myocardin was
overexpressed alone, demonstrating the specificity of the Co-IP
assays.
We used an alternative approach to confirm the interaction
between myocardin and Tbx5. The full-length sequence of the
myocardin gene was fused with the DNA-binding domain of the
Gal4 gene to create a Gal4-myocardin fusion protein (Gal4-
Myocd). The Gal4-myocardin was then transfected with the
pL8G5-luciferase reporter in which the luciferase reporter is under
the control of the Gal4 binding element UAS. Gal4-myocardin,
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the reporter gene (Fig. 3B). Addition of a Tbx5 expression plasmid
further enhanced myocardin activity, indicating that Tbx5 likely
interacted with myocardin directly in this setting (Fig. 3B).
Map the interaction domains of myocardin and Tbx5
To map the domains of myocardin that are responsible for its
interaction with Tbx5, truncated myocardin mutants were
generated and their potential interaction with Tbx5 was examined
by co-immunoprecipitation (Co-IP) assays. The truncation mu-
tants from the N-terminus up to the basic domain of myocardin
can still interact with Tbx5, while further deletion past the basic
domain abolished this capability (Fig. 4A). These results indicate
that the regions between amino acid (aa) 195-267 are required for
myocardin to interact with Tbx5 (Fig. 4A, 4B). To further test
whether the basic domain is critical for the interaction, Co-IP
experiments were performed using a myocardin deletion mutant
lacking only the basic domain [23]. Indeed, the basic domain
deletion myocardin mutant failed to interact with Tbx5 (data not
shown). These results suggest that the basic domain of myocardin
is required for myocardin to mediate its interaction with Tbx5.
Next, we attempted to map the domains of the Tbx5 protein
that mediate its interaction with myocardin. Series of Tbx5
deletion mutants were generated to test their interaction with
myocardin using co-immunoprecipitation (Co-IP) assays. Our
results showed that the N-terminal region (aa 1-100) was sufficient
to interact with myocardin (Fig. 4C, 4D). Similarly, the constructs
(aa 1-300) and (aa 1-400) also interacted with myocardin.
Surprisingly, we found that regions between aa 1-200 failed to
interact with myocardin (Fig. 4C, 4D). This observation is
surprising because a shorter region (aa 1-100) of the Tbx5 protein
was already sufficient to mediate its interaction with myocardin.
One possible reason is that a different conformation is adopted in
the aa 1-200 fragment; alternatively the region between aa 101-
200 may inhibit the interaction between these two proteins.
Consistent with the notion that the N-terminus (aa 1-100) was
Figure 1. Synergistic activation of cardiac but not smooth muscle genes by myocardin and Tbx5. Luciferase reporters directed by cardiac
and smooth muscle gene promoters were co-transfected with myocardin and Tbx5 expression plasmids in COS-7 cells (A-D) or neonatal rat
cardiomyocytes (E). (A) Synergistic activation of the ANF promoter by myocardin and Tbx5. (B) Synergistic activation of the a-MHC promoter by
myocardin and Tbx5. (C) The effect of myocardin and Tbx5 on the SM22 promoter. Myocardin activates the promoter reporter but there is no synergy
between myocardin and Tbx5. (D) The effect of myocardin and Tbx5 on the SM-MHC promoter. Myocardin activates the promoter reporter but there
is no synergy between myocardin and Tbx5. (E) Myocardin and Tbx5 synergistically activate the ANF promoter in neonatal rat cardiomyocytes. In all
experiments, the luciferase activity was determined 48 hr after transfection and was presented as fold of activation in which the control was assigned
a value of 1. Data represent the mean 6 s.d. from at least three independent experiments in duplicate. *P,0.05.
doi:10.1371/journal.pone.0024242.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e24242Figure 2. The TBEs are required for the synergistic activation of ANF promoter by myocardin and Tbx5. (A) COS-7 cells were
transfected with myocardin and Tbx5 expression plasmids and the indicated ANF promoter luciferase reporters in which the CArG boxes and the T-
box factor-Binding Elements (TBEs) were indicated, and luciferase activity measured. (B) COS-7 cells were transfected with an ANF promoter luciferase
reporter (ANF115) or a mutant reporter in which the TBE was mutated (ANF155m) together with myocardin and Tbx5 expression plasmids and
luciferase activity measured. (C) COS-7 cells were transfected with an ANF promoter luciferase reporter (ANF115) (left three lanes) or a mutant
reporter in which the CArG box was mutated (right three lanes) together with myocardin and Tbx5 expression plasmids and luciferase activity
measured. (D) COS-7 cells were transfected with an ANF promoter luciferase reporter (ANF638) (left three lanes) or a mutant reporter in which both
CArG boxes were mutated (ANF638m) (right three lanes) together with myocardin and Tbx5 expression plasmids and luciferase activity measured. (E)
A luciferase reporter controlled by four tandemly repeats of a consensus Tbx binding elements (TBE) was transfected into COS-7 cells with myocardin
and/or Tbx5 expression plasmids and luciferase activity measured. In all the experiments, the luciferase activity was determined 48 hr after
transfection and was presented as relative luciferase activity in which the control was assigned a value of 1. Data represent the mean 6 s.d. from at
least three independent experiments in duplicate. *P,0.05.
doi:10.1371/journal.pone.0024242.g002
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mutant (aa 119-519) lacking this region abolished its myocardin
interaction (Fig. 4C, 4D). Together, these results define the N-
terminal region of the Tbx5 protein as its myocardin interaction
domain.
Myocardin and Tbx5 do not form a stable ternary
complex on DNA elements
Myocardin associates with the CArG boxes via the formation of
a CArG/SRF/myocardin ternary complex [23]. In contrast, Tbx5
directly binds to the TBE sequence on the promoter of its target
genes as a monomer [9,14]. We first tested whether myocardin
affects the binding of Tbx5 to TBE, or myocardin could even form
a ternary complex with Tbx5/TBE. Electrophoretic motility shift
assays (EMSAs) were performed using the conserved TBE
sequences as probes. When Myc-Tbx5 proteins were included
with the probe, there was a very strong band formation (lane 3 in
Fig. 5A), indicating the formation of Tbx5/TBE complex.
Noticeably, there is a non-specific band co-migrating to the same
position as the Tbx5/TBE band, evidenced by its presence in the
control lane in which no proteins were added (lane 1 in Fig. 5A).
The specificity of the Tbx5/TBE complex is further supported by
the formation of ‘‘supershift’’ when Myc antibodies were added
into the reaction (lane 2 in Fig. 5A). Addition of myocardin
proteins did not substantially affect the formation of the Tbx5/
TBE complex, neither did any new band appear (lanes 4–5,
Fig. 5A), suggesting that myocardin does not have a direct effect
on the formation of Tbx5/TBE complex. Myocardin proteins by
themselves did not bind to the TBE probe in the assay (lanes 6-7,
Fig. 5A).
Next, we performed EMSAs to test whether Tbx5 could affect
the formation of myocardin/SRF/CArG ternary complex. When
SRF was incubated with the CArG box probe, they form CArG/
SRF complex (lane 2, Fig. 5B). Inclusion of the anti-SRF
antibodies in the reaction led to a slower migrating band,
representing the CArG/SRF/antibody ‘‘supershift’’, demonstrat-
ing the specificity of protein-DNA complex (lane 3, Fig. 5B).
Inclusion of myocardin and SRF resulted the formation of
myocardin/CArG/SRF ternary complex (lane 5, Fig. 5B). The
formation of the CArG/SRF complex and the myocardin/CArG/
SRF ternary complex was not affected by the addition of Tbx5
proteins (lanes 6 and 8, Fig. 5B), suggesting that TBX5 has no
direct effect on the association of myocardin to the SRF/CArG
complex.
Tbx5 mutation abolishes the synergy with myocardin
Tbx5 has been identified as the Holt-Oram syndrome (HOS)
causative gene. Multiple missense mutations of the human Tbx5
gene have been identified from individuals with HOS [4,40].
Many of these mutations were shown to affect the function of the
Tbx5 protein, including the reduction of its transcriptional
activation ability and the disruption its interaction with protein
co-factors [22]. We tested whether these Tbx5 mutations affect the
synergy between myocardin and Tbx5 to activate the ANF
promoter. An ANF luciferase reporter construct was co-transfected
with expression plasmids encoding myocardin together with wild-
type or mutant Tbx5. It has previously been shown that induction
of missense mutation into Tbx5 did not affect the expression levels
of mutant proteins [22]. Among the mutations tested, Q49K,
I54T, R237Q and R237W did not significantly affect their synergy
with myocardin. However, the Tbx5 G80R mutation abolished
the synergy with myocardin in this assay (Fig. 6).
Discussion
In this study we demonstrated that Tbx5 and myocardin
synergistically activate cardiac gene expression. This activity is
specific to cardiac tissue as these two proteins failed to similarly
regulate smooth muscle genes. Our results therefore reveal a
transcriptional regulatory network for cardiac gene expression.
How do Tbx5 and myocardin cooperate to activate cardiac
gene expression? We found that myocardin and Tbx5 interact
directly and we mapped their interaction domains to the N-termini
of these two proteins. It was known that myocardin does not bind
to DNA directly, but instead associates with SRF to form a
myocardin/SRF/CArG ternary complex on the promoters/
enhancers of its target genes [23,24,25]. Tbx5 directly binds to
the promoters/enhances of its targets on TBE sites to activate the
expression of target genes [4,9]. Our data indicate that the synergy
Figure 3. Myocardin and Tbx5 interact directly. (A) COS-7 cells were transfected with expression plasmids encoding Flag-tagged Tbx5 and
Myc-tagged myocardin as indicated. Tbx5 was immunoprecipitated (IP) by anti-Flag antibodies, and anti-Myc antibodies were used to detect the
presence of myocardin in the immunoprecipitates by Western blot (WB) analysis (upper panel). One-fifteenth of cell extracts were directly Western
blotted (WB) to detect the presence of myocardin and Tbx5 proteins by anti-Myc or anti-Flag antibodies, respectively (middle and lower panels,
respectively). (B) An expression plasmid encoding full-length myocardin (1-935) fused to GAL4 DNA binding domain (Gal4Myocd) and the pL8G5-
luciferase reporter were transfected in the absence or presence of Tbx5 expression plasmid into COS-7 cells and luciferase activity was determined.
pcDNA-Myocardin (Myocd) and pcDNA-Tbx5 (Tbx5) were used as controls. Luciferase activity was determined 48 hr after transfection and was
presented as fold of activation in which the control was assigned a value of 1. Data represent the mean 6 s.d. from at least three independent
experiments in duplicate. *P,0.05.
doi:10.1371/journal.pone.0024242.g003
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ANF promoter. This is consistent with a prior report in which the
TBE sites were shown to be required for the synergistic activation
of ANF by Tbx5 and Nkx2.5 [9]. Whereas our studies
demonstrated that myocardin and Tbx5 physically interact via
protein-protein interaction, they did not appear to enhance each
other’s DNA association on the promoters/enhancers of cardiac
genes. These observations suggest that additional transcriptional
co-factors are likely involved in the regulation of the binding of
myocardin and Tbx5 to target DNAs. It is also possible that the
status of chromatin and histone modification influences the
binding of these two transcription factors to their targets.
Myocardin is expressed in both cardiac and smooth muscle cells
and is capable of activating both cardiac and smooth muscle-
specific gene expression. How is the specificity defined? We
observed that the interaction between Tbx5 and myocardin helps
Figure 4. Mapping of the myocardin and Tbx5 interaction domains. (A) COS-7 cells were transfected with expression plasmids encoding
Myc-tagged Tbx5 and a collection of Flag-tagged myocardin deletion mutants. Tbx5 was immunoprecipitated (IP) by anti-Myc antibodies, and anti-
Flay antibodies were used to detect the presence of myocardin in the immunoprecipitates by immunoblot analysis (IB) (upper panel). One-fifteenth
of cell extracts were directly immunoblotted (IB) to detect the presence of myocardin and Tbx5 proteins by anti-Flag or anti-Myc antibodies,
respectively (middle and lower panels, respectively). (B) A schematic summary of myocardin and Tbx5 protein interaction domains. Myocardin
domains abbreviated as follows: B, basic domain; Q, a stretch of glutamine residues; SAP, SAF A/B, Acinus, PIAS domain; TAD, transactivation domain.
(C) COS-7 cells were transfected with expression plasmids encoding Flag-tagged myocardin and a collection of Myc-tagged Tbx5 deletion mutants.
Myocardin was immunoprecipitated (IP) by anti-Flag antibodies, and anti-Myc antibodies were used to detect the presence of Tbx5 in the
immunoprecipitates by immunoblot (IB) analysis (upper panel). One-fifteenth of cell extracts were directly immunoblotted (IB) to detect the presence
of Tbx5 and myocardin proteins by anti-Myc or anti-Flag antibodies, respectively (middle and lower panels, respectively). (D) A schematic summary of
myocardin and Tbx5 protein interaction domains.
doi:10.1371/journal.pone.0024242.g004
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profiles. In differentiating smooth muscle cells, Tbx5 staining
showed that it was present only in the cytoplasm, instead of the
nucleus [41]. Therefore the expression of cardiac genes in smooth
muscle cells won’t be activated by the cooperation of Tbx5 and
myocardin; however, the activation of smooth muscle genes by
myocardin is not affected. Previous studies suggest that the cellular
localization of Tbx5 protein might be controlled by its interaction
partners, such as LMP4 [41,42]. It will be important to determine
whether subcellular location of the Tbx5 proteins contributes to its
function in the control of cardiac and smooth muscle gene
expression.
Tbx5 belongs to the family of T-box containing transcription
factors. Several members of this family of transcription factors are
also expressed in the heart. Interestingly, Tbx2 was shown to
repress the expression of the ANF gene, in part, by impairing the
recruitment of Nkx2.5 to the TBE or the NKE [43]. On the other
hand, Tbx20 was reported to synergize with Tbx5 to activate
cardiac gene expression [44,45]. Our data demonstrate that Tbx5
and myocardin synergistically activate the expression of cardiac,
but not smooth muscle genes. It will be interesting to test whether
other members of the Tbx family of transcription factors will also
physically and functionally interact with myocardin to regulate
cardiac (and smooth muscle) gene expression during development.
Multiple missense mutations of the human Tbx5 gene have
been associated with the HOS. Interestingly, these mutations do
not uniformly impair the function of Tbx5 in the same manner.
For example, Tbx5 mutations G80R and R237Q have different
effects on its synergistic transactivation of the cardiac-specific ANF
gene, which will likely translate as subtle differences in the
phenotype and severity of the HOS [14]. The Tbx5 G80R mutant
displayed more severe defect in co-operating with Nkx2.5 to
activate the ANF than that of the R237Q mutant [14,21]. In
addition, the synergy of Tbx5 with Sall4 was slightly reduced by
mutations Q49K and T54I but dramatically impaired by
mutations Q80R and R237W for FGF10 activation [21]. Given
the fact that the expression of Tbx5 downstream genes is
significantly affected by the dosage of Tbx5 [4], it is reasonable
to speculate that the interaction between Tbx5 and myocardin
may differentially affect the expression of some genes, like ANF,
but not others like SM22. The molecular mechanisms uncovered
in this study suggest that the interaction of transcription factors
contribute to the expression of their target genes and human
disease.
Materials and Methods
Plasmids and Constructs
Myocardin and SRF-expression plasmids were described
previously [23,27,34]. The mouse Tbx5 gene was cloned from a
mouse cDNA library and constructed in Myc- and Flag-tagged
pCDNA3.1 expression vectors. Myc and Flag-tagged plasmids
were used for immuno-precipitation and Western blot experi-
ments. Luciferase reporters under the control of the atrial
natriuretic factor (ANF) promoter, truncated ANF promoter,
ANF promoter with mutated CArG, 4XCArG, 4XTBE or the
SM22 promoter, a-myosin heavy chain (MHC), smooth muscle
MHC (SM MHC), as well as the cytomegalovirus lacZ and the
Gal4-myocardin construct were as described previously
[23,33,34,36]. Gal4-Tbx5 was constructed by inserting the mouse
Tbx5 coding cDNA into the EcoRI and XbaI sites of the pM1
vector (Invitrogen). Truncated Tbx5 mutants were generated by
PCR with the oligonucleotides for the desired sites in the pMyc-
cDNA vector. Tbx5 missense mutants (Q49K, I54T, G80R,
R237Q and R237W) were as described previously [22].
Cell Culture, Transfection and Luciferase Reporter Assays
COS-7 cells were maintained in DMEM with 10% FBS as
described [23,35,37]. The cells were seeded on plates and
Figure 5. Tbx5 and myocardin do not form a stable ternary
complex on CArG-box or TBE. Myc-tagged Tbx5 and Flag-tagged
myocardin proteins were expressed by in vitro transcription and
translation and incubated with radiolabeled probes. (A) Electrophoresis
mobility shift assays were performed with a
32P-labeled TBE probe for
Myc-tagged Tbx5 in the presence and absence of increasing amount of
Flag-myocardin. Anti-Myc antibodies were applied for supershift. The
Tbx5/TBE complexes and the supershift complex were indicated. (B)
Electrophoresis mobility shift assays were performed with a
32P-labeled
CArG probe for Flag-myocardin in the presence and absence of SRF, or
in the presence and absence of Myc-Tbx5. Anti-SRF antibodies were
applied for supershift. The SRF/CArG complexes (SRF), the Myocd/SRF/
CArG ternary complexes (SRF+Myocd) and supershift complex (Super-
shift) were indicated.
doi:10.1371/journal.pone.0024242.g005
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protocol provided by the manufacturer. The amount of each type
of plasmids was 0.1 mg unless stated otherwise in the text. The total
amount of DNA was normalized to the same with the addition of
vector DNA. The cells were lysed 48 hrs later and luciferase
activity was measured using assay kit (Promega) and the lacZ
activity was measured to serve as internal control as described
[35]. All experiments were performed in duplicate and repeated at
least twice.
Ethics Statement
Neonatal rat cardiomyocytes were prepared as described [23].
All animal procedures were approved by and performed in
accordance with the University of North Carolina Institutional
Animal Care and Use Committee under the protocol 08-227.0.
Co-immunoprecipitation (Co-IP) and Western blot
Co-IP and Western blot analyses were performed as described
[23,35]. Briefly, COS-7 cells in 10-cm plates were transfected with
Myc- or Flag- tagged Tbx5 and/or myocardin. After 2 days, the
cells were harvested in lysis buffer (20 mM Tris, 150 mM NaCl,
0.5% Triton X-100, 1 mM EDTA, pH 7.5) containing protease
inhibitors (Roche) and 1 mM phenylmethylsulfonyl fluoride. The
lysates were centrifuged at 14,000x RPM for 10 minutes after
sonication for 15 seconds for 3 times. The supernatants were
added anti-Myc antibodies and incubated at 4uC for 2 hours, or
protein A-agarose beads were added and incubated for 1 more
hour. For immunoprecipitation with anti-Flag antibodies, the anti-
M2 Agarose beads (Sigma) were added into the cell lysate and
incubated for 4 hours at 4uC. Then the beads were spin down and
washed with lysis buffer 3 times. The bound proteins were eluted
with SDS loading buffer and used for Western blot analysis with
anti-Myc (1:2500; C14, Santa Cruz Biotechnology) and anti-Flag
(1:2500; M2 Sigma) antibodies.
Electrophoresis mobility shift assay (EMSA)
EMSAs were performed as described previously [35,36]. The
probes were CArG [36] and T-box factor-Binding Element, TBE2
(the up-strand sequence was 59CTCTTCTCACACCTTT-
GAAGTGGG39). The probes were labeled as described [36]
and the EMSA procedures were performed as previously
described [36].
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